Truist Financial Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target dropped by research analysts at Truist Financial from $820.00 to $818.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s target price points to a potential upside of 7.75% from the stock’s previous close.

Several other equities analysts also recently weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Hsbc Global Res raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Scotiabank increased their target price on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. Finally, Evercore ISI lifted their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $790.64.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $759.18 on Monday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.77 and a quick ratio of 4.22. The stock’s fifty day moving average price is $757.70 and its two-hundred day moving average price is $654.25. The firm has a market cap of $79.79 billion, a PE ratio of 18.27, a PEG ratio of 1.95 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the company earned $12.07 EPS. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Insiders Place Their Bets

In related news, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. increased its stake in Regeneron Pharmaceuticals by 55.2% in the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after buying an additional 6,073 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its position in shares of Regeneron Pharmaceuticals by 153.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock valued at $67,969,000 after acquiring an additional 73,176 shares in the last quarter. PGGM Investments boosted its stake in shares of Regeneron Pharmaceuticals by 9.7% in the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after acquiring an additional 8,187 shares during the period. Bellecapital International Ltd. lifted its holdings in Regeneron Pharmaceuticals by 32.7% in the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock worth $13,389,000 after purchasing an additional 6,283 shares in the last quarter. Finally, Rakuten Investment Management Inc. bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $33,121,000. 83.31% of the stock is currently owned by institutional investors.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target to $950 and kept an “overweight” rating — a sizable increase that signals strong analyst conviction and adds meaningful upside to the stock. Benzinga
• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and lifted its target to $865, reflecting continued confidence after Regeneron’s Q4 beat. Benzinga
• Positive Sentiment: Cantor Fitzgerald raised its target to $800 and maintained an “overweight” view, another vote of confidence supporting the rally. Benzinga
• Positive Sentiment: Wells Fargo lifted its price target to $800 (equal weight) — a modest boost that still reinforces momentum from the quarter. Benzinga
• Positive Sentiment: Regeneron highlighted new EYLEA HD presentations (QUASAR and ELARA results) at Angiogenesis 2026 — positive clinical data that can support the ophthalmology franchise outlook. EYLEA HD Presentations
• Positive Sentiment: Coverage roundup notes analysts revising forecasts after Regeneron’s upbeat Q4 results—consensus attention on the beat is lifting sentiment. Analyst Revisions After Q4
• Neutral Sentiment: Morgan Stanley nudged its target to $769 but kept an “equal weight” rating — a very small adjustment that signals limited near‑term upside from their view. TickerReport
• Neutral Sentiment: Market commentary pieces discuss Regeneron’s pipeline progress and valuation gap; useful context for longer‑term investors but not an immediate catalyst. Yahoo Finance
• Negative Sentiment: Truist trimmed its target slightly to $818 (still a “buy”) — a small downward tweak that may temper upside expectations from some investors. Benzinga

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.